Abstract: The present invention provides an electrolyte component containing one or more salts including lithium bis(oxalate)borate (LiBOB), a solvent, propylene carbonate (PC) and a crystallisable polymer wherein said LiBOB is present as a weight percentage of 0.5% or more, said propylene carbonate is present as a weight percentage of between 5% and 90% and the crystallisable polymer is present at a weight percentage of greater than 1%. It also provides a galvanic cell formed from the above and a process for forming same.

Abstract: A kiwifruit plant particularly distinguished by very early maturing fruit, hairless fruit surface with conspicuous mid brown lenticels, yellow fruit flesh, ovoid longitudinal and circular cross section fruit shape, slightly blunt protruding stylar end, is described.

Abstract: Provided are compounds of Formula I, stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, and methods of manufacturing a compound of Formula I.

Abstract: This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a KD of 10 pM or less when measured by Kinexa™. The binding members are useful for, inter alia, treatment of disorders mediated by IL-1R1 including rheumatoid arthritis, asthma and chronic obstructive pulmonary disease (COPD).

Abstract: Provided are compounds of Formula I, stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, and methods of manufacturing a compound of Formula I.

Abstract: In one embodiment of the invention a catheter (203) comprises a body having at least one inlet aperture (21, 24), at least one outlet aperture (22, 25), and at least one passage (20, 23) between the at least one inlet aperture (21, 24) and the at least one outlet aperture (22, 25). The catheter (203) is provided with pumping means (32) for selectively pumping fluid from one of said apertures (21, 22, 24, 25) to another of said apertures (21, 22, 24, 25). Methods of operating such a catheter are also disclosed.

Abstract: A method of performing distributed just-in-time compilation includes sending a first request message from a client platform to a dedicated compilation server requesting just-in-time compilation of a bytecode sequence generated from a set of code for a source program executing on the client platform; compiling the bytecode sequence at the compilation server into a set of machine code instructions executable by the client platform; storing the set of machine code instructions in a repository managed by the dedicated compilation server; sending a notification message indicating that the set of machine code instructions are available from the dedicated compilation server to the client platform; sending a second request message from the client platform to the dedicated compilation server requesting the set of machine code instructions; and accessing the repository to send the set of machine code instructions from the dedicated compilation server to the client platform.

Abstract: The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, B, D, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and methods of use thereof.

Abstract: A monitoring system for monitoring the integrity of a member disposed within a machine includes an image analyzer configured to receive image data from an imaging device and to determine an amount of radiation incident on one or more of one or more pixels of the imaging device. The monitoring system also includes a monitor coupled to the image analyzer and configured to generate an alarm in the event an amount of radiation on one or more of the one or more pixels exceeds a limit.

Abstract: The current invention provides a method for mobilizing endothelial progenitor cells (EPC) and/or mesenchymal stem cells (MSC) in a patient, wherein the method comprises the steps of (i) administering a vascular endothelial growth factor receptor (VEGFR) agonist to the patient; and (ii) administering an antagonist of CXCR4 to the patient. Also provided are uses of EPC and MSC harvested using the methods of the invention.

Abstract: This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a KD of 10 pM or less when measured by Kinexa™. The binding members are useful for, inter alia, treatment of disorders mediated by IL-1R1 including rheumatoid arthritis, athma and chronic obstructive pulmonary disease (COPD).

Abstract: A particulate filtration reverse pulse cleaning system is disclosed. The system comprising a housing, a tubesheet disposed within the housing, a filter for fluid communication with a tubesheet aperture, a support frame connectable with the tubesheet, and a cleaning system associated with the support frame. A filter cleaning system is also disclosed, the support frame comprising a plurality of hollow support legs comprising at least one cleaning aperture and a cleaning system associated with the plurality of hollow support legs. A method for cleaning a filter is also disclosed.

Abstract: An axle assembly (310) has a longitudinal axis and first and second ends, the axle assembly configured for rotatably mounting a wheel and hub assembly on an axle portion or the axle assembly, the axle portion located between the first and second ends, the axle assembly configured for affixing to first and second structural members (301, 302), at least one of the structural members (302) comprising a substantially closed bore orifice (306) wheel mounting point or dropout, said dropout having a first side configured for the axle portion to extend therefrom when said axle assembly (310) is fixed to said point and a second side, the axle assembly (310) comprising a first fixing means (309) at the first end for releasably fixing the axle assembly (310) to the first structural member (302) and a second fixing means (311) at the second end fog releasably fixing the axle assembly (310) to the second structural member (301).

Abstract: Binding members, e.g. human antibody molecules, which bind interleukin-6 (IL-6) and neutralise its biological effects. Use of binding members for IL-6 in medical treatment e.g. for treating inflammatory diseases and tumours associated with IL-6.

Abstract: This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a KD of 10 pM or less when measured by Kinexa™. The binding members are useful for, inter alia, treatment of disorders mediated by IL-1R1 including rheumatoid arthritis, asthma and chronic obstructive pulmonary disease (COPD).

Abstract: Provided are compounds of Formula I, stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, and methods of manufacturing a compound of Formula I.

Abstract: A liquid applicator for applying a liquid sample to a liquid receiving surface is disclosed. The liquid applicator comprises a bibulous line to hold a first predetermined volume of liquid for application to a liquid receiving surface. A second predetermined volume less than or equal to the first predetermined volume is applied to the liquid receiving surface in a substantially uniform and consistent pattern. Systems and methods for using embodiments of the liquid applicators are also disclosed.

Abstract: Binding members, e.g. human antibody molecules, which bind interleukin-6 (IL-6) and neutralize its biological effects. Use of binding members for IL-6 in medical treatment e.g. for treating inflammatory diseases and tumors associated with IL-6.

Abstract: An authentication device (100) for use with electronic security devices and user authentication systems is disclosed. The authentication device includes a data store (104) for storing plural secret keys, each secret key associated with a corresponding service, a service selection means (101) for selecting a service from the corresponding services, an authentication code generator (102) for generating, from the secret key associated with the selected service, a one time usable authentication code for communication to an authentication controller associated with the selected service, and an output (106) for outputting the generated authentication code for communication to the authentication controller. A method of authentication a user to a service is also disclosed.

Abstract: A kiwifruit plant particularly distinguished by very early maturing fruit, hairless fruit surface with conspicuous mid brown lenticels, yellow fruit flesh, ovoid longitudinal and circular cross section fruit shape, slightly blunt protruding stylar end, is described.